|
|
Article: Study shows that second-generation PSA test can differentiate between prostate cancer and BPH up to seven years before diagnosis of prostate cancer; May help detect prostate cancer earlier than the PSA test; Clinical data to be presented at AUA annual meeting May 7 in Orlando.
- Article from:
- Business Wire
- Article date:
- May 3, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
STRATFORD, Conn.--(BUSINESS WIRE)--May 3, 1996--Researchers at Johns Hopkins University Medical Center and DIANON Systems Inc. (NASDAQ: DIAN) have determined that a second-generation PSA test may be useful in discriminating between prostate cancer and BPH, or benign prostatic hyperplasia, up to seven years before prostate cancer is diagnosed.
A study describing this breakthrough development will be presented at next week's 1996 Annual Meeting of the American Urological Association (AUA) in Orlando, Fla.
Prostate specific antigen (PSA) is widely used as a clinical marker of prostate cancer. The PSA test measures blood levels of a protein that is secreted by ...